XtalPi Advances Oral Peptide and Pan-TEAD Inhibitor Pipeline Amid High Valuation Concerns

XtalPi Announces FDA Approval for Oral Peptide Drug to Enter Clinical Trials; Pan-TEAD Cancer Inhibitor Development Accelerated. Its market capitalization stands at approximately HK$35 billion, with a trailing P/E ratio of 275x, and it currently generates no significant revenue from products.

XtalPi Pharma’s oral peptide drug targeting metabolic diseases has received FDA Investigational New Drug (IND) approval, with Phase I clinical trials originally scheduled to commence in the first quarter; Xinzhi Pharma’s pan-TEAD inhibitor SIGX2649 has advanced from preclinical development to the IND application stage, with Phase I clinical trials expected to begin in the third quarter.

The market for oral peptide drugs already has successful products, while XtalPi’s drug candidate has only received approval for clinical trials. There are no commercialized drugs in the therapeutic area targeted by SIGX2649; although preclinical data are promising, the TEAD inhibition field poses significant risks for small companies. The first-in-human administration of SIGX2649 will test whether it can avoid the pitfall of off-target toxicity.

XtalPi’s recent cash inflows have come from collaboration milestone payments, and it has also issued RMB 2.5 billion in convertible bonds, while burning through cash to build an unvalidated drug development pipeline.

Biotech company valuations are based on catalytic events rather than profitability, but XtalPi’s valuation gap is significant; it is not worth HK$35 billion unless both drugs become blockbusters and the company executes flawlessly.

Valuation should consider the reasonable price in case of a project's success; current valuations may already reflect the best-case scenario, meaning setbacks would have a more severe impact. The upcoming release of Phase I clinical trial data will distinguish between companies whose valuations are well-deserved and those supported merely by luck.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on publicly available information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express